About this Journal Submit a Manuscript Table of Contents
ISRN Hematology
Volume 2011 (2011), Article ID 124610, 7 pages
http://dx.doi.org/10.5402/2011/124610
Review Article

Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management

Thrombosis and Vascular Diseases Laboratory, Health Innovations Research Institute and School of Medical Sciences, RMIT University, P.O. Box 71, Bundoora, VIC 3083, Australia

Received 19 July 2011; Accepted 9 August 2011

Academic Editors: J. Batlle, P. Chiusolo, and P. Imbach

Copyright © 2011 Fatemeh Moheimani and Denise E. Jackson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Gibbs, J. Fletcher, P. Blombery, et al., “Venous thromboembolism prophylaxis guideline implementation is improved by nurse directed feedback and audit,” Thrombosis Journal, vol. 9, no. 1, p. 7, 2011.
  2. National Health and Medical Research Council, Stop the Clot: Integrating VTE Prevention Guideline Recommendations into Routine Hospital Care, National Health and Medical Research Council, 3rd edition, 2011, http://www.nhmrc.gov.au/.
  3. I. A. Naess, S. C. Christiansen, P. Romundstad, et al., “Incidence and mortality of venous thrombosis: a population-based study,” Journal of Thrombosis and Haemostasis, vol. 5, no. 4, pp. 692–699, 2007.
  4. D. Scarvelis and P. S. Wells, “Diagnosis and treatment of deep-vein thrombosis,” CMAJ, vol. 175, no. 9, pp. 1087–1092, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. Kearon, “Natural history of venous thromboembolism,” Circulation, vol. 107, no. 23, supplement 1, pp. I22–I30, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. W. K. Ho, “Deep vein thrombosis risks and diagnosis,” Australian Family Physician, vol. 39, no. 7, pp. 468–474, 2010. View at Scopus
  7. R. H. White, “The epidemiology of venous thromboembolism,” Circulation, vol. 107, no. 23, supplement 1, pp. I4–I8, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. V. Snow, A. Qaseem, P. Barry et al., “Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians,” Annals of Internal Medicine, vol. 146, no. 3, pp. 204–210, 2007. View at Scopus
  9. S. R. Kahn, “The post thrombotic syndrome,” Thrombosis Research, vol. 127, supplement 3, pp. S89–S92, 2011.
  10. G. Agnelli and C. Becattini, “Acute pulmonary embolism,” The New England Journal of Medicine, vol. 363, no. 3, pp. 210–274, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. McRae, “Pulmonary embolism,” Australian Family Physician, vol. 39, no. 6, pp. 462–466, 2011. View at Scopus
  12. J. A. Heit, “Venous thromboembolism: disease burden, outcomes and risk factors,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1611–1617, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. D. W. Barritt and S. C. Jordan, “Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial,” The Lancet, vol. 275, no. 7138, pp. 1309–1312, 1960. View at Scopus
  14. J. D. Douketis, C. Kearon, S. Bates, E. K. Duku, and J. S. Ginsberg, “Risk of fatal pulmonary embolism in patients with treated venous thromboembolism,” Journal of the American Medical Association, vol. 279, no. 6, pp. 458–462, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. F. A. Anderson and F. A. Spencer, “Risk factors for venous thromboembolism,” Circulation, vol. 107, no. 23, supplement 1, pp. I9–I16, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. V. De Stefano, G. Finazzi, and P. M. Mannucci, “Inherited thrombophilia: pathogenesis, clinical syndromes, and management,” Blood, vol. 87, no. 9, pp. 3531–3544, 1996. View at Scopus
  17. F. R. Rosendaal and P. H. Reitsma, “Genetics of venous thrombosis,” Journal of Thrombosis and Haemostasis, vol. 7, supplement 1, pp. 301–304, 2009.
  18. S. Ota, N. Yamada, Y. Ogihara, et al., “High plasma level of factor VIII,” Circulation Journal, vol. 75, no. 6, pp. 1472–1475, 2011.
  19. T. Koster, A. D. Blann, E. Briet, J. P. Vandenbroucke, and F. R. Rosendaal, “Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis,” The Lancet, vol. 345, no. 8943, pp. 152–155, 1995. View at Scopus
  20. M. Den Heijer, S. Lewington, and R. Clarke, “Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies,” Journal of Thrombosis and Haemostasis, vol. 3, no. 2, pp. 292–299, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. A. V. H. Vlieg, N. Komanasin, R. A. Ariens, et al., “Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis,” The British Journal of Haematology, vol. 119, no. 1, pp. 169–175, 2002.
  22. P. S. Wells, D. R. Anderson, J. Bormanis et al., “Value of assessment of pretest probability of deep-vein thrombosis in clinical management,” The Lancet, vol. 350, no. 9094, pp. 1795–1798, 1997. View at Publisher · View at Google Scholar
  23. P. S. Wells, D. R. Anderson, M. Rodger et al., “Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis,” The New England Journal of Medicine, vol. 349, no. 13, pp. 1227–1235, 2003. View at Publisher · View at Google Scholar · View at PubMed
  24. H. Bounameaux, A. Perrier, and M. Righini, “Diagnosis of venous thromboembolism: an update,” Vascular Medicine, vol. 15, no. 5, pp. 399–406, 2010. View at Publisher · View at Google Scholar · View at PubMed
  25. F. A. Klok, E. Kruisman, J. Spaan et al., “Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism,” Journal of Thrombosis and Haemostasis, vol. 6, no. 1, pp. 40–44, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. F. A. Klok, I. C. Mos, M. Nijkeuter et al., “Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism,” Archives of Internal Medicine, vol. 168, no. 19, pp. 2131–2136, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. Penaloza, C. Melot, S. Motte, et al., “Comparison of the Wells score with the simplified revised Geneva score for assessing pretest probability of pulmonary embolism,” Thrombosis Research, vol. 127, no. 2, pp. 81–84, 2011.
  28. R. P. Engelberger, D. Aujesky, L. Calanca, et al., “Comparison of the diagnostic performance of the original and modified Wells score in inpatients and outpatients with suspected deep vein thrombosis,” Thrombosis Research, vol. 127, no. 6, pp. 535–539, 2011.
  29. M. Reichert, T. Henzler, and R. Krissak, “Venous thromboembolism: additional diagnostic value and radiation dose of pelvic CT venography in patients with suspected pulmonary embolism,” European Journal of Radiology, vol. 80, no. 1, pp. 50–53, 2011.
  30. P. D. Stein, S. E. Fowler, L. R. Goodman et al., “Multidetector computed tomography for acute pulmonary embolism,” The New England Journal of Medicine, vol. 354, no. 22, pp. 2317–2327, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. H. Kume, Y. Inoue, A. Mitsuoka, N. Sugano, T. Morito, and T. Muneta, “Doppler ultrasonography-aided early diagnosis of venous thromboembolism after total knee arthroplasty,” European Journal of Vascular and Endovascular Surgery, vol. 40, no. 5, pp. 664–668, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. S. J. McRae and J. W. Eikelboom, “Latest medical treatment strategies for venous thromboembolism,” Expert Opinion on Pharmacotherapy, vol. 8, no. 9, pp. 1221–1233, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. D. G. MacLellan and J. P. Fletcher, “Mechanical compression in the prophylaxis of venous thromboembolism,” ANZ Journal of Surgery, vol. 77, no. 6, pp. 418–423, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. J. Hirsh and R. Raschke, “Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy,” Chest, vol. 126, no. 3, pp. 188S–203S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Hirsh, M. O'Donneill, and J. I. Weitz, “New anticoagulants,” Blood, vol. 105, no. 2, pp. 453–463, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. A. Weltermann, P. A. Kyrle, and S. Eichinger, “Novel anticoagulants for the prevention and treatment of venous thromboembolism,” Wiener Medizinische Wochenschrift, vol. 153, no. 19-20, pp. 426–433, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. A. C. Spyropoulos, “Managing oral anticoagulation requires expert experience and clinical evidence,” Journal of Thrombosis and Thrombolysis, vol. 21, no. 1, pp. 91–94, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. A. Lee, G. Agnelli, H. Büller et al., “Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement,” Circulation, vol. 104, no. 1, pp. 74–78, 2001. View at Scopus
  39. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux, “Rivaroxaban: a new oral factor xa inhibitor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 3, pp. 376–381, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. H. R. Büller, B. L. Davidson, H. Decousus et al., “Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism,” The New England Journal of Medicine, vol. 349, no. 18, pp. 1695–1702, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. H. R. Büller, B. L. Davidson, H. Decousus et al., “Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial,” Annals of Internal Medicine, vol. 140, no. 11, pp. 867–873, 2004. View at Scopus
  42. B. I. Eriksson, L. C. Borris, O. E. Dahl et al., “Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement,” Thrombosis Research, vol. 120, no. 5, pp. 685–693, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. B. I. Eriksson, L. Borris, O. E. Dahl et al., “Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 121–128, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. B. I. Eriksson, L. C. Borris, O. E. Dahl et al., “A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement,” Circulation, vol. 114, no. 22, pp. 2374–2381, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. G. Turpie, W. D. Fisher, K. A. Bauer et al., “BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study,” Journal of Thrombosis and Haemostasis, vol. 3, no. 11, pp. 2479–2486, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. L. M. Kwong, “Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty,” The American Journal of Managed Care, vol. 17, no. 1, pp. S22–S26, 2011.
  47. H. Buller, D. Deitchman, M. Prins, and A. Segers, “Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study,” Journal of Thrombosis and Haemostasis, vol. 6, no. 8, pp. 1313–1318, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick, “Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial,” The Lancet, vol. 375, no. 9717, pp. 807–815, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. R. Lassen, A. Gallus, G. E. Raskob, G. Pineo, D. Chen, and L. M. Ramirez, “Apixaban versus enoxaparin for thromboprophylaxis after hip replacement,” The New England Journal of Medicine, vol. 363, no. 26, pp. 2487–2498, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial,” The Lancet, vol. 370, no. 9591, pp. 949–956, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. C. Kearon and M. O'Donnell, “Graduated compression stockings to prevent venous thromboembolism in hospital: evidence from patients with acute stroke,” Polskie Archiwum Medycyny Wewnętrznej, vol. 121, no. 1-2, pp. 40–43, 2011.
  53. J. B. Long, “Venous thromboembolism: pharmacological and nonpharmacological interventions,” Journal of Cardiovascular Nursing, vol. 24, no. 6, pp. S8–S13, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. J. A. Caprini, “Mechanical methods for thrombosis prophylaxis,” Clinical and Applied Thrombosis/Hemostasis, vol. 16, no. 6, pp. 668–673, 2011.
  55. H. Partsch and W. Blättler, “Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin,” Journal of Vascular Surgery, vol. 32, no. 5, pp. 861–869, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. P. Prandoni, A. W. A. Lensing, M. H. Prins et al., “Below-knee elastic compression stockings to prevent the post-thrombotic syndrome. A randomized, controlled trial,” Annals of Internal Medicine, vol. 141, no. 4, pp. 249–256, 2004. View at Scopus
  57. A. K. Wittkowsky, E. A. Nutescu, and E. B. Devine, “Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?” Journal of Thrombosis and Thrombolysis, vol. 26, no. 3, pp. 248–250, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. Dennis, P. A. Sandercock, J. Reid, et al., “Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial,” The Lancet, vol. 373, no. 9679, pp. 1958–1965, 2009.
  59. The CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration, “Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial,” Annals of Internal Medicine, vol. 153, no. 9, pp. 553–562, 2010.
  60. A. G. G. Turpie, K. A. Bauer, J. A. Caprini, P. C. Comp, M. Gent, and J. E. Muntz, “Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison,” Journal of Thrombosis and Haemostasis, vol. 5, no. 9, pp. 1854–1861, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus